Company news
Shanghai Henlius Biotech, Inc. news in 2026
Shanghai Henlius Biotech, Inc.'s news releases, calls and decks from 2026, newest first.
Voluntary announcement - the application for the phase 1 clinical trial of HLX105 for injection (anti-PD-1 antibody-IL-2 variant fusion protein) for the treatment of advanced/metastatic solid tumours has been approved by the national medical products administration
November 16, 2026
Voluntary announcement - inclusion of HANSIZHUANG (serplulimab injection) and others in the national reimbursement drug list
November 15, 2026
Voluntary announcement - the phase 1 clinical trial of HLX109 injection (a monoclonal antibody targeting IL1RAP) for the treatment of generalized pustular psoriasis has been approved to commence in australia
November 4, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 3, 2026
Documents on Display - CONTINUING CONNECTED TRANSACTION - REVISION OF ANNUAL CAP FOR THE COLLABORATION ARRANGEMENTS UNDER THE HLX01 AGREEMENT
November 2, 2026
Proxy form for the 2026 first extraordinary general meeting to be held on Monday, 23 November 2026 (or any adjournment thereof)
November 2, 2026
Notice of extraordinary general meeting
November 2, 2026
(1) Continuing connected transaction revision of annual cap for the collaboration arrangements under the HLX01 agreement (2) proposed appointment of non-executive director and independent non-executive director and notice of extraordinary general meeting
November 2, 2026
Continuing connected transaction - revision of annual cap for the collaboration arrangements under the HLX01 agreement
October 27, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 6, 2026
List of directors and their roles and functions
September 30, 2026
(1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees
September 30, 2026
Interim report 2026
September 24, 2026
Voluntary announcement - collaboration and license agreement with amberstone for two T Cell Engager products
September 23, 2026
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
August 21, 2026
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
August 21, 2026
Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
August 17, 2026
FDA Approves Shanghai Henlius Biotech IND For Cetuximab Biosimilar
May 28, 2026
Henlius Announces IND Approval from NMPA for Its Proprietary c-Met/EGFR Bispecific ADC HLX48
May 22, 2026
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
April 29, 2026
NMPA Grants IND Approval for Henlius Nivolumab Biosimilar HLX18 Following U.S. FDA Clearance
March 23, 2026
Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
March 20, 2026
Henlius Obtains Japan MAH License Strengthening Presence in the World's Fourth-Largest Pharmaceutical Market
March 2, 2026
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 5, 2026
Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
January 16, 2026
Henlius Fifth U.S. Filing Product Bevacizumab Biosimilar HLX04 Receives FDA BLA Acceptance
January 14, 2026
Decks in 2026
- H1 2026 Earnings Presentation
Earnings · 49 slides · Aug 21, 2026
- Technical Presentation (May 2026)
Technical · 10 slides · May 31, 2026
- FY2025 Earnings Presentation
Earnings · 53 slides · Mar 20, 2026